Objective： To investigate the effect of Xiaoyu Zhixue Tablet （消瘀止血片, XYZXT） on the expression of platelet membrane glycoprotein （GP） Ⅰ b/Ⅸ/Ⅴ complex and GP Ⅰ b α in patients with chronic renal failure ...Objective： To investigate the effect of Xiaoyu Zhixue Tablet （消瘀止血片, XYZXT） on the expression of platelet membrane glycoprotein （GP） Ⅰ b/Ⅸ/Ⅴ complex and GP Ⅰ b α in patients with chronic renal failure （CRF） in early metaphase. Methods： Fifty-one patients with CRF in early metaphase （treated group） were treated with XYZXT, 3 months as the course of treatment for 2 courses. The previous therapies remained unchanged. Flow cytometry was used to assess the expression of platelet GP Ⅰb/Ⅸ/Ⅴ complex and GP Ⅰb α in patients with CRF, and turbidity method was used to determine the platelet maximum aggregation rate （MAR）, meanwhile the renal function was measured. The final data were compared with those before the treatment, and with those in the normal control group （31 healthy subjects）. Results： Compared with the normal control group, expressions of GP Ⅰ b/Ⅸ/Ⅴ complex and GPⅠb α, and platelet MAR in CRF patients were significantly lower （P=0.007,P=0.001,P=0.009） before the treatment; after the treatment with XYZXT, the above indexes in CRF patients were remarkably increased （P=0.033,P=0.026, P=0.045）, but still lower than those in the normal control group, however, it was not statistically significant. Conclusion： （1） The expression of GP Ⅰ b/Ⅸ/Ⅴ complex in CRF patients of early metaphase was decreased, which lead to platelet aggregation dysfunction. This might be one of the reasons for the hemorrhagic trend in CRF. （2） XYZXT was able to upgrade expressions of GP Ⅰb/Ⅸ/Ⅴ complex and GPⅠb α in CRF patients, improve platelet function and clown-regulate platelet activation in patients with CRF.展开更多
目的 探讨冠心病患者血小板聚集功能在不同临床分型、不同冠脉病变支数水平变化及与同型半胱氨酸(Hcy)、超敏C反应蛋白(hs-CRP)相关性。方法 回顾性分析唐山市第三医院首次确诊的冠心病患者152例,按照冠状动脉造影结果将冠心病患者分为...目的 探讨冠心病患者血小板聚集功能在不同临床分型、不同冠脉病变支数水平变化及与同型半胱氨酸(Hcy)、超敏C反应蛋白(hs-CRP)相关性。方法 回顾性分析唐山市第三医院首次确诊的冠心病患者152例,按照冠状动脉造影结果将冠心病患者分为单支病变组和多支病变组;再按应激状态分为急性冠脉综合征(ACS)组和非ACS组,分析以二磷酸腺苷(ADP)和花生四烯酸(AA)为诱导剂的血小板聚集功能在各组间的变化,探讨其与Hcy、hs-CRP的相关性。结果 单支病变组和多支病变组以ADP和AA为诱导剂的最大血小板聚集率比较差异均无统计学意义( P >0.05);ACS组与非ACS组以ADP和AA为诱导剂的最大血小板聚集率比较差异均有统计学意义( P <0.05);冠心病患者hs-CRP、Hcy水平与AA、ADP诱导的最大血小板聚集率呈显著的正相关( r 1=0.29、0.33;r 2=0.37、0.34, P <0.05)。结论 最大血小板聚集率在ACS、非ACS患者中呈现不同的变化且与hs-CRP、Hcy密切相关,对冠心病的诊断、治疗、危险评估有一定的参考价值。展开更多
基金the National Natural Science Foundation of China(No.30572441)
文摘Objective： To investigate the effect of Xiaoyu Zhixue Tablet （消瘀止血片, XYZXT） on the expression of platelet membrane glycoprotein （GP） Ⅰ b/Ⅸ/Ⅴ complex and GP Ⅰ b α in patients with chronic renal failure （CRF） in early metaphase. Methods： Fifty-one patients with CRF in early metaphase （treated group） were treated with XYZXT, 3 months as the course of treatment for 2 courses. The previous therapies remained unchanged. Flow cytometry was used to assess the expression of platelet GP Ⅰb/Ⅸ/Ⅴ complex and GP Ⅰb α in patients with CRF, and turbidity method was used to determine the platelet maximum aggregation rate （MAR）, meanwhile the renal function was measured. The final data were compared with those before the treatment, and with those in the normal control group （31 healthy subjects）. Results： Compared with the normal control group, expressions of GP Ⅰ b/Ⅸ/Ⅴ complex and GPⅠb α, and platelet MAR in CRF patients were significantly lower （P=0.007,P=0.001,P=0.009） before the treatment; after the treatment with XYZXT, the above indexes in CRF patients were remarkably increased （P=0.033,P=0.026, P=0.045）, but still lower than those in the normal control group, however, it was not statistically significant. Conclusion： （1） The expression of GP Ⅰ b/Ⅸ/Ⅴ complex in CRF patients of early metaphase was decreased, which lead to platelet aggregation dysfunction. This might be one of the reasons for the hemorrhagic trend in CRF. （2） XYZXT was able to upgrade expressions of GP Ⅰb/Ⅸ/Ⅴ complex and GPⅠb α in CRF patients, improve platelet function and clown-regulate platelet activation in patients with CRF.
文摘目的 探讨冠心病患者血小板聚集功能在不同临床分型、不同冠脉病变支数水平变化及与同型半胱氨酸(Hcy)、超敏C反应蛋白(hs-CRP)相关性。方法 回顾性分析唐山市第三医院首次确诊的冠心病患者152例,按照冠状动脉造影结果将冠心病患者分为单支病变组和多支病变组;再按应激状态分为急性冠脉综合征(ACS)组和非ACS组,分析以二磷酸腺苷(ADP)和花生四烯酸(AA)为诱导剂的血小板聚集功能在各组间的变化,探讨其与Hcy、hs-CRP的相关性。结果 单支病变组和多支病变组以ADP和AA为诱导剂的最大血小板聚集率比较差异均无统计学意义( P >0.05);ACS组与非ACS组以ADP和AA为诱导剂的最大血小板聚集率比较差异均有统计学意义( P <0.05);冠心病患者hs-CRP、Hcy水平与AA、ADP诱导的最大血小板聚集率呈显著的正相关( r 1=0.29、0.33;r 2=0.37、0.34, P <0.05)。结论 最大血小板聚集率在ACS、非ACS患者中呈现不同的变化且与hs-CRP、Hcy密切相关,对冠心病的诊断、治疗、危险评估有一定的参考价值。
